Raiden commences airborne geophysical survey on Majdanpek JV project

|

Published 06-AUG-2018 13:06 P.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

FinFeed presents this information for the use of readers in their decision to engage with this product. Please be aware that this is a very high-risk product. We stress that this article should only be used as one part of this decision-making process. You need to fully inform yourself of all factors and information relating to this product before engaging with it.

Copper-gold exploration company Raiden Resources Limited (ASX:RDN) is targeting the emerging prolific Tethyan metallogenic belt in eastern Europe, primarily in Serbia.

The company has recently formed an JV with Rio Tinto (ASX:RIO) in respect to two of its six projects — Majdanpek West, Majdanpek Pojas and Donje Nevlje — whereby RIO can earn a 75 per cent project-level position in the properties via a staged exploration commitment totalling US$31.5 million.

RDN has now commenced an airborne, versatile time domain electromagnetic survey (VTEM) on the Majdanpek project.

The survey is a helicopter supported system, proprietary to Geotech and consists of an electromagnetic induction loop transmitter and receiver carried underneath a helicopter to allow close terrain hugging surveys. The configuration will also carry a magnetometer to allow for the simultaneous acquisition of airborne magnetics.

The VTEM system is designed to detect and map electrical conductors at depth. This technique is effective for detection of massive sulphide lenses and connected disseminated sulphide mineralisation. Sulphides and clay zones within structures may be associated with the porphyry copper mineralisation, alteration and associated epithermal alteration zones. Some epithermal deposits, such as Cukaru Peki near Bor, are associated with large massive sulphide bodies.

Overall this is an early stage play and as such any investment decision should be made with caution and professional financial advice should be sought.

The Majdanpek project license is located adjacent to RTB Bor’s Majdanpek open pit mine, which is developed on a large copper-gold porphyry. Less than one kilometre to the south west of the project boundary, RTB Bor have defined a prospect consisting of an epithermal related copper-gold-silver-zinc massive sulphide body of unknown size and grade (Coka Marin).

RDN-RIO JV Majdanpek West and Majdanpek Pojas licenses (red), in relation to other deposits

The exploration program on the project will be targeting similar style of porphyry and epithermal style mineralisation.

Managing Director Dusko Ljubojevic stated: “The commencement of the VTEM survey at Majdanpek is a significant milestone For Raiden. This project is truly in elephant country and we are excited to have access to the vast experience Rio Tinto contribute in this geological terrain.

“The company remains well capitalised for its 2018 exploration program as we continue to systematically evaluate targets over our highly prospective project portfolio in the world class Tethyan Belt in Serbia. This methodical approach will allow for a seamless transition between targets as we continue our aggressive exploration campaign.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X